An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder

• Published in: International journal of psychiatry in clinical practice 2014-01, Vol.18 (1), p.11-15
• Main Authors: Kaplan, Alicia, Franzen, Michael D., Nickell, P. V., Ransom, Danielle, Lebovitz, Paul J.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Analysis of Variance; Anxiety Disorders - drug therapy; Anxiety Disorders - epidemiology; Anxiety Disorders - psychology; Comorbidity; duloxetine; Duloxetine Hydrochloride; Female; generalized anxiety disorder; Humans; Irritable bowel syndrome; Irritable Bowel Syndrome - drug therapy; Irritable Bowel Syndrome - epidemiology; Irritable Bowel Syndrome - psychology; Male; Middle Aged; Outcome Assessment (Health Care) - statistics & numerical data; Pilot Projects; Placebos; Quality of Life; Serotonin Uptake Inhibitors - administration & dosage; Serotonin Uptake Inhibitors - therapeutic use; Severity of Illness Index; Single-Blind Method; Thiophenes - administration & dosage; Thiophenes - therapeutic use; Young Adult
• ISSN: 1365-1501; 1471-1788
• DOI: 10.3109/13651501.2013.838632

Abstract Objective. Irritable bowel syndrome (IBS) is commonly comorbid with generalized anxiety disorder (GAD). We evaluated whether duloxetine would lead to improvement in symptoms and quality of life in patients with both conditions. Method. A 12-week, open-label trial of duloxetine was conducted in 13 subjects with IBS and GAD. The primary outcome measure was the Clinical Global Impression (CGI) Scale. Secondary measures included the Hamilton Anxiety Rating Scale, IBS Quality of Life (IBS-QOL) Scale, and IBS Symptom Severity Scale (IBS-SSS). Results. Repeated measures ANOVA was used to examine the effect of treatment with duloxetine on ratings of anxiety and IBS. Significant improvement was observed on the CGI-Improvement (F = 14.19, df = 1,12, p < 0.001) and Severity scales (F = 16.16, df = 1,12, p < 0.001). Secondary measures revealed significant reduction in symptoms of anxiety (F = 11.66, df = 1,12, p < 0.01), ηp2 = 0.56, and IBS-SSS (F = 6.05, df = 1,12, p < 0.001), ηp2 = 0.34, in addition to IBS-QOL improvements (F = 11.66, df = 1,12, p < 0.01), ηp2 = 0.56. Conclusion. Results of this pilot study support the efficacious use of duloxetine in comorbid IBS and GAD. Participants reported significant reductions in IBS components, as well as improvement in GAD.